Company news
Intellia Therapeutics, Inc. news in 2024
Intellia Therapeutics, Inc.'s news releases, calls and decks from 2024, newest first.
Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Nexiguran Ziclumeran (nex-z) for the Treatment of Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy
November 24, 2024
Intellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression in Transthyretin (ATTR) Amyloidosis
November 15, 2024
Intellia Therapeutics Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress
November 6, 2024
Intellia Therapeutics Announces Two Upcoming Investor Events in November 2024
October 30, 2024
Intellia Presents Positive Results from the Phase 2 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)
October 23, 2024
Intellia Therapeutics Announces New Date for Upcoming Investor Webcast
October 9, 2024
Intellia Therapeutics Announces Initiation of HAELO Phase 3 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)
October 6, 2024
Intellia Therapeutics to Present New Clinical Data from the Phase 1 Study of nexiguran ziclumeran (nex-z) for the Treatment of Transthyretin (ATTR) Amyloidosis at the 2024 AHA Scientific Sessions
September 30, 2024
Intellia Therapeutics to Present Data from the Phase 2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the 2024 ACAAI Annual Scientific Meeting
September 11, 2024
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
September 2, 2024
Intellia Therapeutics Announces Second Quarter 2024 Financial Results and Highlights Recent Company Progress
August 7, 2024
Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2024 Earnings and Company Updates
July 31, 2024
Intellia Therapeutics Receives Authorization to Initiate Phase 1/2 Clinical Trial of NTLA-3001 for the Treatment of Alpha-1 Antitrypsin Deficiency
July 29, 2024
Intellia Therapeutics Announces CFO Transition
June 25, 2024
Intellia Announces Positive Clinical Proof-of-Concept Data for Redosing a CRISPR-Based Therapy with its Proprietary LNP-Based Delivery Platform
June 24, 2024
Intellia Therapeutics to Present the First-Ever Clinical Data From Patients Redosed with an Investigational In Vivo CRISPR Gene Editing Therapy at the Peripheral Nerve Society Annual Meeting 2024
June 16, 2024
Intellia Therapeutics Names Brian Goff to its Board of Directors
June 13, 2024
Intellia Therapeutics Announces Positive Long-Term Data from Ongoing Phase 1 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)
June 1, 2024
Intellia Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress
May 8, 2024
Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2024 Earnings and Company Updates
May 1, 2024
Intellia Therapeutics to Present Updated Data from Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the EAACI Congress 2024
April 28, 2024
Intellia Therapeutics Announces First Patient Dosed in the Phase 3 MAGNITUDE Study of NTLA-2001 as a Single-Dose CRISPR-Based Treatment for Transthyretin Amyloidosis with Cardiomyopathy
March 17, 2024
Intellia Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Company Progress
February 21, 2024
Intellia Therapeutics and ReCode Therapeutics Announce Strategic Collaboration to Develop Novel Gene Editing Therapies for Cystic Fibrosis
February 14, 2024
Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2023 Earnings and Company Updates
February 13, 2024
Intellia Therapeutics Announces Publication of Positive Interim Phase 1 Data for NTLA-2002 in Patients with Hereditary Angioedema in the New England Journal of Medicine
January 30, 2024
Intellia Therapeutics Highlights its Three-Year Strategic Priorities and Anticipated 2024 Key Milestones
January 3, 2024
Calls in 2024
- Intellia Therapeutics (NASDAQ:NTLA) Q3 2024 Earnings Call
Nov 7, 2024
Transcript - Intellia Therapeutics (NASDAQ:NTLA) Q2 2024 Earnings Call
Aug 8, 2024
Transcript - Intellia Therapeutics (NASDAQ:NTLA) Q1 2024 Earnings Call
May 9, 2024
Transcript - Intellia Therapeutics (NASDAQ:NTLA) Q4 2023 Earnings Call
Feb 22, 2024
Transcript
Decks in 2024
- Technical Presentation (October 2024)
Technical · 29 slides · Oct 24, 2024
- Technical Presentation (June 2024)
Technical · 29 slides · Jun 3, 2024